The roles and clinical applications of interleukins in endometrial carcinoma.

Yuqin Zang, Huanrong Li, Shiqi Liu, Ruqian Zhao, Kaiwen Zhang, Yuqi Zang, Yingmei Wang, Fengxia Xue
Author Information
  1. Yuqin Zang: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  2. Huanrong Li: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  3. Shiqi Liu: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  4. Ruqian Zhao: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  5. Kaiwen Zhang: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  6. Yuqi Zang: Hangzhou College of Preschool Teacher Education, Zhejiang Normal University, Hangzhou, China.
  7. Yingmei Wang: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
  8. Fengxia Xue: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.

Abstract

As a common malignant tumor of the female reproductive system, endometrial carcinoma (EC) seriously endangers women's health with an increasing incidence. The oncogenesis and progression of cancer are closely linked with immune microenvironment, of which interleukins are the important components. In order to illustrate the roles and clinical applications of interleukins in EC, literature of interleukins and EC were reviewed. Based on the present studies, interleukins play crucial roles in the oncogenesis and development of EC regulating the proliferation, migration, invasion, angiogenesis, apoptosis, pyroptosis and autophagy of EC as well as the immune function against EC. And some of the interleukins seems to have prospective clinical applications in EC, such as evaluating the risk of tumorigenesis, discriminating the malignancy from benign disorders or normal condition, indicating cancer aggressiveness, predicting the prognosis of patients and serving as the novel therapy. However, there is still a long way to go before the clinical applications of interleukins in EC come into reality. Nevertheless, it is certain that the exploration of interleukins will definitely be of great benefit to the screening, diagnosis and treatment of EC in the future.

Keywords

References

  1. Immunol Rev. 2017 May;277(1):61-75 [PMID: 28462526]
  2. Clin Exp Med. 2007 Mar;7(1):6-10 [PMID: 17380299]
  3. Int J Gynecol Cancer. 2012 Nov;22(9):1500-8 [PMID: 23051953]
  4. BMC Cancer. 2022 Jan 18;22(1):77 [PMID: 35042454]
  5. Gynecol Oncol. 1989 Aug;34(2):195-9 [PMID: 2787771]
  6. Mol Cancer Ther. 2016 Apr;15(4):720-30 [PMID: 26846819]
  7. Ann N Y Acad Sci. 1995 Sep 7;766:235-44 [PMID: 7486666]
  8. J Tradit Chin Med. 2019 Apr;39(2):160-165 [PMID: 32186037]
  9. Genes (Basel). 2022 May 24;13(6): [PMID: 35741697]
  10. Int J Mol Sci. 2020 May 27;21(11): [PMID: 32471032]
  11. Eur J Cancer. 2002 Nov;38 Suppl 6:S76-7 [PMID: 12409086]
  12. Mol Med. 2019 Jul 12;25(1):32 [PMID: 31299894]
  13. Heliyon. 2021 Dec 29;8(1):e08696 [PMID: 35036597]
  14. Front Oncol. 2019 Oct 01;9:969 [PMID: 31681561]
  15. Growth Factors. 2012 Feb;30(1):29-36 [PMID: 22010785]
  16. Int J Biol Sci. 2011 Jan 18;7(1):74-86 [PMID: 21278918]
  17. Cancer Immunol Res. 2014 Mar;2(3):194-9 [PMID: 24778315]
  18. Biochem Biophys Res Commun. 2014 Mar 28;446(1):167-72 [PMID: 24582558]
  19. Front Immunol. 2019 Jun 25;10:1426 [PMID: 31293586]
  20. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):971-7 [PMID: 21415362]
  21. Biochem Biophys Res Commun. 2018 Jun 7;500(3):626-631 [PMID: 29684351]
  22. Mol Cancer Ther. 2010 Jan;9(1):57-66 [PMID: 20053761]
  23. Gynecol Oncol. 1991 Aug;42(2):161-4 [PMID: 1832651]
  24. Bull Exp Biol Med. 2010 Dec;150(2):243-6 [PMID: 21240383]
  25. J Cell Biochem. 2010 May 15;110(2):447-56 [PMID: 20235152]
  26. Biomed Pharmacother. 2020 Apr;124:109831 [PMID: 31972354]
  27. Fundam Clin Pharmacol. 2017 Aug;31(4):438-446 [PMID: 28299811]
  28. Evid Based Complement Alternat Med. 2022 Jun 13;2022:8330926 [PMID: 35774749]
  29. Cancer Manag Res. 2020 Apr 30;12:2993-3002 [PMID: 32431542]
  30. Int J Immunogenet. 2020 Apr;47(2):169-174 [PMID: 31981288]
  31. Dis Markers. 2016;2016:9262919 [PMID: 27340318]
  32. Int J Cancer. 2014 Jul 15;135(2):282-94 [PMID: 24347287]
  33. Br J Cancer. 2010 Sep 7;103(6):812-9 [PMID: 20700124]
  34. Sci Rep. 2020 Apr 29;10(1):7226 [PMID: 32350297]
  35. Oncol Rep. 2012 May;27(5):1488-96 [PMID: 22327423]
  36. J Clin Immunol. 1993 Jul;13(4):259-64 [PMID: 8227285]
  37. Tumour Biol. 2016 Apr;37(4):4721-6 [PMID: 26511973]
  38. Int J Oncol. 2012 Aug;41(2):759-64 [PMID: 22614117]
  39. Cancer Res. 2016 Mar 15;76(6):1354-66 [PMID: 26744532]
  40. J Clin Endocrinol Metab. 1998 May;83(5):1783-7 [PMID: 9589693]
  41. Int J Gynecol Cancer. 2011 Dec;21(9):1533-9 [PMID: 21912264]
  42. Cell Death Differ. 2015 Feb;22(2):237-46 [PMID: 25190142]
  43. Int J Cancer. 2017 Feb 1;140(3):600-610 [PMID: 27770434]
  44. Asian Pac J Cancer Prev. 2018 Apr 25;19(4):969-975 [PMID: 29693365]
  45. Oncol Rep. 2007 Mar;17(3):617-22 [PMID: 17273742]
  46. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  47. Int J Oncol. 2017 Mar;50(3):798-804 [PMID: 28098860]
  48. J Cancer Res Clin Oncol. 1997;123(3):167-72 [PMID: 9119882]
  49. Int J Biochem Cell Biol. 2014 Oct;55:335-47 [PMID: 25194337]
  50. Tumour Biol. 2015 Jul;36(7):5265-72 [PMID: 25663496]
  51. Clin Exp Immunol. 2004 Sep;137(3):546-51 [PMID: 15320904]
  52. Clin Cancer Res. 2008 May 15;14(10):3089-97 [PMID: 18483376]
  53. Pharmaceuticals (Basel). 2021 Jul 06;14(7): [PMID: 34358075]
  54. Biomedicines. 2022 May 20;10(5): [PMID: 35625926]
  55. Oncology. 2006;71(1-2):95-101 [PMID: 17341889]
  56. PLoS One. 2012;7(1):e30840 [PMID: 22295114]
  57. Cancer Res. 2004 Sep 15;64(18):6482-8 [PMID: 15374958]
  58. J Biochem Mol Toxicol. 2022 Jun;36(6):e23027 [PMID: 35266250]
  59. Mol Cell Biochem. 2014 Mar;388(1-2):219-31 [PMID: 24287565]
  60. J Obstet Gynaecol Res. 2016 Aug;42(8):983-9 [PMID: 27136893]
  61. J Clin Oncol. 1990 Oct;8(10):1618-29 [PMID: 2213099]
  62. Nat Med. 2020 May;26(5):650-651 [PMID: 32405061]
  63. Cancer. 2011 Jul 15;117(14):3163-72 [PMID: 21246534]
  64. Gynecol Oncol. 2012 Apr;125(1):114-9 [PMID: 22198242]
  65. Int J Biol Sci. 2020 Jun 14;16(13):2323-2339 [PMID: 32760201]
  66. Oncol Lett. 2019 Aug;18(2):1424-1430 [PMID: 31423207]
  67. Int J Clin Exp Pathol. 2020 Jun 01;13(6):1324-1332 [PMID: 32661468]
  68. Int Immunopharmacol. 2021 Sep;98:107836 [PMID: 34218217]
  69. Int J Gynecol Cancer. 2001 Jan-Feb;11(1):54-60 [PMID: 11285034]
  70. Int J Cancer. 1986 Sep 15;38(3):331-8 [PMID: 3488968]
  71. Neoplasia. 2018 Jan;20(1):69-79 [PMID: 29195127]
  72. Immunity. 2019 Apr 16;50(4):851-870 [PMID: 30995503]
  73. Cancer Lett. 2002 Aug 8;182(1):19-26 [PMID: 12175519]
  74. Mol Genet Genomic Med. 2019 Apr;7(4):e00600 [PMID: 30828987]
  75. Gynecol Oncol. 2005 Jul;98(1):92-8 [PMID: 15904949]
  76. Front Oncol. 2020 Sep 04;10:1697 [PMID: 33014844]
  77. Cancer Res. 2015 Sep 1;75(17):3608-22 [PMID: 26130650]
  78. Gynecol Oncol. 2002 Jun;85(3):423-30 [PMID: 12051868]
  79. Clin Transl Radiat Oncol. 2021 Jun 09;29:60-64 [PMID: 34159263]
  80. Acta Histochem. 2006;108(1):13-8 [PMID: 16564564]
  81. Pathol Res Pract. 2019 Jun;215(6):152392 [PMID: 30922625]
  82. J Biol Chem. 1999 Oct 15;274(42):30196-201 [PMID: 10514510]
  83. Nat Rev Cancer. 2019 Sep;19(9):510-521 [PMID: 31388127]
  84. Cell Transplant. 2022 Jan-Dec;31:9636897221104452 [PMID: 35712817]
  85. Med Oncol. 2020 Sep 14;37(10):90 [PMID: 32926243]
  86. Am J Pathol. 2010 Jan;176(1):435-45 [PMID: 20008143]
  87. Anticancer Res. 2014 Jan;34(1):379-83 [PMID: 24403491]
  88. Eur J Cancer Prev. 2013 Jul;22(4):374-9 [PMID: 23702681]
  89. Reprod Biol Endocrinol. 2010 Jun 17;8:63 [PMID: 20553623]
  90. Biochem Biophys Res Commun. 1997 Sep 18;238(2):338-42 [PMID: 9299508]
  91. Int J Clin Exp Pathol. 2018 Feb 01;11(2):894-903 [PMID: 31938181]
  92. PLoS One. 2020 Apr 21;15(4):e0231594 [PMID: 32315343]
  93. PLoS One. 2021 Mar 9;16(3):e0248103 [PMID: 33690729]
  94. Front Med (Lausanne). 2022 Mar 01;9:822806 [PMID: 35299842]
  95. BMC Cancer. 2020 Jan 10;20(1):28 [PMID: 31924176]
  96. Lab Invest. 2021 Jun;101(6):760-774 [PMID: 33753880]
  97. Int J Cancer. 1987 Oct 15;40(4):479-83 [PMID: 3499400]
  98. PLoS One. 2013 Jul 26;8(7):e68923 [PMID: 23922669]
  99. Gynecol Endocrinol. 1998 Oct;12(5):315-9 [PMID: 9859023]
  100. Nat Rev Rheumatol. 2020 Jun;16(6):335-345 [PMID: 32327746]
  101. Int J Cancer. 2021 Apr 1;148(7):1708-1716 [PMID: 33285000]
  102. Clin Cancer Res. 2002 May;8(5):1271-9 [PMID: 12006548]
  103. Mol Oncol. 2013 Feb;7(1):41-54 [PMID: 22944067]
  104. Sci Rep. 2015 Aug 04;5:12781 [PMID: 26239551]
  105. Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [PMID: 19348862]
  106. Jpn J Cancer Res. 2002 Jun;93(6):626-35 [PMID: 12079510]
  107. Am J Cancer Res. 2016 Jan 15;6(2):200-13 [PMID: 27186396]
  108. Front Immunol. 2020 Nov 19;11:544248 [PMID: 33329510]
  109. Gen Physiol Biophys. 2019 Jan;38(1):63-71 [PMID: 30657459]
  110. J Obstet Gynaecol Res. 2021 Jul;47(7):2449-2459 [PMID: 33969570]
  111. Cancer Sci. 2009 Jun;100(6):1051-61 [PMID: 19432902]
  112. J Immunol Res. 2022 Jun 2;2022:3815853 [PMID: 35692503]
  113. Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [PMID: 19509143]
  114. Int J Oncol. 2015 Oct;47(4):1451-9 [PMID: 26316317]
  115. Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [PMID: 18980965]
  116. Sci Rep. 2017 Nov 9;7(1):15172 [PMID: 29123149]
  117. J Interferon Cytokine Res. 2021 Jan;41(1):12-19 [PMID: 33471616]
  118. J Cancer. 2022 Mar 6;13(5):1603-1610 [PMID: 35371322]
  119. Biol Pharm Bull. 2004 Feb;27(2):156-61 [PMID: 14758024]
  120. J Immunol Res. 2020 Oct 13;2020:9731049 [PMID: 33110923]
  121. Immunity. 2019 Apr 16;50(4):892-906 [PMID: 30995505]
  122. Biomed Res Int. 2021 Jul 14;2021:4804694 [PMID: 34337010]
  123. Anticancer Res. 1994 Mar-Apr;14(2B):735-7 [PMID: 8010733]
  124. Gynecol Oncol. 2016 Feb;140(2):239-44 [PMID: 26644265]
  125. Int J Mol Sci. 2021 Mar 15;22(6): [PMID: 33804263]
  126. Endocr Connect. 2019 Jul;8(7):961-968 [PMID: 31189128]
  127. J Int Med Res. 2020 Sep;48(9):300060520950563 [PMID: 32878530]
  128. Br J Cancer. 2010 Jan 5;102(1):134-43 [PMID: 19920829]
  129. Ann Oncol. 2002 Mar;13(3):430-4 [PMID: 11996475]
  130. Cancers (Basel). 2022 Jan 06;14(2): [PMID: 35053431]
  131. Biomol Ther (Seoul). 2021 Nov 1;29(6):650-657 [PMID: 34607979]
  132. Toxicol In Vitro. 2015 Mar;29(2):308-13 [PMID: 25433332]
  133. Int J Oncol. 2017 May;50(5):1778-1784 [PMID: 28339086]
  134. Pathol Oncol Res. 2016 Oct;22(4):825-9 [PMID: 27193105]
  135. Nature. 2013 May 2;497(7447):67-73 [PMID: 23636398]
  136. Int J Cancer. 2008 Dec 15;123(12):2782-90 [PMID: 18798554]
  137. J Biol Response Mod. 1990 Dec;9(6):538-45 [PMID: 2074440]
  138. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Jun;33(3):292-8 [PMID: 21718613]
  139. Immunity. 2019 Apr 16;50(4):871-891 [PMID: 30995504]
  140. Evid Based Complement Alternat Med. 2021 Dec 02;2021:6053406 [PMID: 34899952]
  141. Oncotarget. 2017 Apr 4;8(14):22716-22729 [PMID: 28186993]
  142. Front Immunol. 2020 Jun 12;11:1124 [PMID: 32655554]
  143. Dis Markers. 2017;2017:8248175 [PMID: 28659656]
  144. Cancer Lett. 2015 Oct 28;367(2):103-7 [PMID: 26188281]
  145. Am J Epidemiol. 2013 Apr 15;177(8):787-99 [PMID: 23492765]
  146. Int J Gynecol Cancer. 2017 Feb;27(2):196-205 [PMID: 27870715]
  147. Biochem Biophys Res Commun. 2021 Apr 9;548:204-210 [PMID: 33647797]
  148. PLoS One. 2017 Oct 9;12(10):e0184576 [PMID: 28991928]
  149. Gynecol Oncol. 2014 Mar;132(3):599-605 [PMID: 24388919]
  150. Jpn J Cancer Res. 2001 Jul;92(7):726-34 [PMID: 11473722]

Word Cloud

Created with Highcharts 10.0.0ECinterleukinsclinicalapplicationsendometrialcancerrolescarcinomaoncogenesisimmunecommonmalignanttumorfemalereproductivesystemseriouslyendangerswomen'shealthincreasingincidenceprogressioncloselylinkedmicroenvironmentimportantcomponentsorderillustrateliteraturereviewedBasedpresentstudiesplaycrucialdevelopmentregulatingproliferationmigrationinvasionangiogenesisapoptosispyroptosisautophagywellfunctionseemsprospectiveevaluatingrisktumorigenesisdiscriminatingmalignancybenigndisordersnormalconditionindicatingaggressivenesspredictingprognosispatientsservingnoveltherapyHoweverstilllongwaygocomerealityNeverthelesscertainexplorationwilldefinitelygreatbenefitscreeningdiagnosistreatmentfutureapplicationexpressioninterleukinmechanism

Similar Articles

Cited By (4)